Drugmaker Shire bids $30 billion for Baxter spin-off Baxalta

LONDON (Reuters) – Drugmaker Shire said on Tuesday it was seeking to buy Baxalta , a company spun-off by Baxter International last month, for $30 billion to forge the leading global specialist in rare diseases.

Leave a Comment

START TYPING AND PRESS ENTER TO SEARCH